Meet the Team
Koon Yan "Chris" Pak, Ph.D.
Co-Founder and Chief Executive Officer
Dr. Pak has been in the Biotechnology field for over two decades. He was
formerly associated with Centocor, a top-tier biopharmaceutical company,
now a subsidiary of Johnson and Johnson.
Dr. Pak has served as the
President of the Chinese American Society of Nuclear Medicine, the Vice
Steven Brem, MD
Chief Medical Officer
Dr. Brem is the Chief of Neurosurgical Oncology, Co-director of Penn Brain Tumor Center and Professor of Neurosurgery at University of Pennsylvania, Perelman School of Medicine. Dr. Brem is a renowned clinical research scientist who sits on the scientific/medical advisory boards of several cancer research associations including American Association of Cancer Research, American Brain Tumor Association and Brain Tumor Action Network among others. Dr. Brem has extensive clinical research experience in many types of tumors. He has reviewed and approved 127 tumor trial protocols in University of Pennsylvania and at Moffitt Cancer Center. Dr. Brem is currently the principle investigator of six cancer trials, including two NIH funded and four industry sponsored trials. He has published more than 100 clinical research articles in peer-reviewed journals and presented more than 100 posters in medical conferences such as ASCO (American Society of Clinical Oncology).
Jeffrey A. Mattis, Ph.D.
Senior Vice President of Scientific & Regulatory Affairs
Dr. Mattis is a biopharmaceutical executive with more than 30 years experience in the technical development of biopharmaceuticals. Dr. Mattis previously served as Vice President of Pharmaceutical Development for Centocor. Dr. Mattis was instrumental in the technical development of several biopharmaceuticals approved for the US and multinational markets. These include ReoPro®, an anti-platelet drug for use in coronary angioplasty; Remicade®, a drug for treatment of Crohn’s disease and rheumatoid arthritis; and Myoscint®, a cardiac imaging agent.
Brian D. Gray, Ph.D.
Vice President of Research
Dr. Gray earned a Ph.D. in Organic Chemistry in 1983 from the University of Dundee, Scotland, and carried out post-doctoral research involving the synthesis of complex organic molecules first initially at Oregon State University and then at SmithKline Beckman. In 1988 he helped co-found Zynaxis, Inc., a biotechnology company, with colleagues from SmithKline, and rose to the position of Director of Medicinal Chemistry. From 1997 until May 2007 he served as V.P. of Chemical Research for PTI Research, Inc. (PTIR), a firm that provides contract and custom chemistry services for life science and pharmaceutical researchers in academia and industry, specializing in the synthesis of heterocyclic organics, bioconjugates, and compounds requiring complex multistep syntheses. He was also the PI on several NIH grants while at PTIR and was responsible for the design and development of novel research reagents for neuronal tract tracing (NeuroVue® dyes) and cell tracking (CellVue® dyes) now being manufactured and sold by MTTI. Dr Gray has more than 25 years experience in the design and synthesis of novel compounds for biomedical research, diagnostics and drug delivery applications, with special expertise in the chemistry of fluorescent dyes and lipophilic agents.
Michael Silvon, Ph.D., MBA
Senior Vice President of Business Development
Dr. Silvon is a seasoned CRO operations, strategic planning and M&A Executive. He has created, fixed and grown multiple high science, heavily regulated life science services businesses. Dr. Silvon is experienced in driving profitable, pragmatic molecular biology, microbiology, virology, synthesis, bioanalysis, preclinical and clinical testing lab operations.
Dr. Silvon has developed strategic plans for multiple employers and consulting clients and orchestrated 6 acquisitions from planning to closing for four firms, all preceded by screening and due diligence against strategic selection criteria. All included detailed integration plans. Attentive to critical leadership, financial, people/culture, markets and competitive technology performance drivers, Dr. Silvon ran integrated businesses for 3 of these long-term. As VP of Global Biopharmaceutical Services he grew value in microbiology lab under Charles River through improved staff efficiencies, focused QA, automation, RMM, streamlined reporting and acquisition assessment. He optimizes investor value, grounded in broad, proactive finance community relationships.
Jianwei Xu, Ph.D
Chief Business Officer
Dr. Xu has over 9 years of experience in the pharmaceutical industry in consulting and investment roles. His most recent positions include Decision Analysis Advisor at Chevron and Director of Decision Analysis and Portfolio Management at Johnson & Johnson Pharmaceutical R&D. Dr. Xu started his consulting career as an associate at McKinsey & Company where he worked with middle and upper management of major pharmaceutical companies on planning and implementing strategies for achieving a superior competitive position. He conducted clinical operations benchmarking among leading global pharmaceutical companies to improve clinical trial operations, facilitated the merger of two major global pharmaceutical companies’ animal health divisions, designed the commercial and R&D organizations of the merged division, identified licensing and acquisition targets for a major pharmaceutical company and helped it to round out its product portfolio and maintain annual revenue growth rate of 10%. He has identified and evaluated major trends that will impact Pharmaceutical industry valuation in the next decade and levers that pharmaceutical companies can pull to unlock value. He also designed a go-to-market strategy for a major cardiovascular medical device product.
Dr. Xu has extensive experience in competitive intelligence and competitive strategies and directed global CI projects serving major pharmaceutical companies. He managed a multi-national team to conduct competitive intelligence research and analysis, and helped pharmaceutical clients plan R&D, BD&L and commercial strategies based on the competitive market landscape. He is responsible for the equity research of a start-up hedge fund. Dr. Xu has a PhD in neuroscience from SUNY at Buffalo and a B.S. in chemistry from University of Science and Technology of China.
Ban An Khaw, Ph.D.
Dr. Khaw is a leading authority in the field of cardiac imaging and new technology development. He co-developed Myoscint for myocardial infarct detection with Dr. Edgar Haber (former President of Bristol-Myers-Squibb). Dr. Khaw has been with the Harvard Medical School and the Massachusetts General Hospital, Division of Nuclear Medicine, Department of Radiology and the Cardiac Unit for almost three decades, and is currently the Director of the Center for Drug Targeting and Analysis, at the Bouve College of Pharmacy and Health Sciences at Northeastern University. Dr. Khaw is a pioneer in the application of immunological methods in the diagnosis of cardiovascular diseases, as well as being an inventor for a dozen of patents. Currently, he is on the editorial boards of Bioconjugate Chemistry and American Journal of Nuclear Cardiology.
Professor Fabian Kiessling, M.D., Ph.D.
Professor Fabian Kiessling has been head of the Institute of Experimental Molecular Imaging at the Helmholtz Center of Applied Engineering of the RWTH-University in Aachen, Germany since 2008. Dr. Kiessling’s research has focused on the development of novel probes and imaging tools for diagnosis and monitoring of disease-specific angiogenesis related processes. Professor Kiessling studied Medicine and received his Ph.D. from the University in Heidelberg. After serving as a resident in the Department of Radiology at the German Cancer Research Center (DKFZ) in Heidelberg he joined the Department of Medical Physics in Radiology as leader of the Molecular Imaging group in 2003. He completed his clinical training at the University of Heidelberg and received board certification as a Radiologist in 2007, and his Habilitation in experimental radiology in 2006. Dr. Kiessling has authored more than 200 scientific publications and book chapters, edited two books and received many research awards, including the “Emil Salzer Prize for Cancer Research” and the “Richtzenhain Prize”. Professor Kiessling serves on the Editorial board of several scientific journals including Radiology, European Radiology, American Journal of Nuclear Medicine and Molecular Imaging, Current Medicinal Chemistry, Frontiers in Bioscience and the Open Organic Chemistry Journal. He is a founding member of the European Society for Functional and Molecular Imaging in Radiology (ESMOFIR), currently treasurer of the European Society for Molecular Imaging (ESMI), a founding member of the ESMI working group “Image Guided Therapy and Drug Delivery (IGTDD) “chairman of the “Molecular Imaging” subcommittee of the European Society for Radiology (ESR) and a member of the program committee of the World Molecular Imaging Conference (WMIS).
Guiliano Mariani, M.D.
Dr. Mariani is Full Professor of Nuclear Medicine and Director of the Postgraduate Specialty School in Nuclear Medicine at the University of Pisa Medical School, and Director of the Regional Center of Nuclear Medicine of the University Hospital of Pisa, Italy. He has been in the field of Nuclear Medicine for over 35 years, initially involved in pharmacokinetic studies with radioactive tracers in humans, then in all other aspects of diagnostic and therapeutic Nuclear Medicine. His expertise has developed through several collaborations with other disciplines and with other institutions, including extended stays at the National Cancer Institute, Bethesda, MD (1974-1976), and at the Harvard Medical School, Boston, MA (1986-1990). Dr. Mariani is currently International Associate Editor of “The Journal of Nuclear Medicine,” and member of the Editorial Board of the “European Journal of Nuclear Medicine and Molecular Imaging,” “The Quarterly Journal of Nuclear Medicine,” and of other prestigious international journals. He is the current President of the Italian Study Group of RadioImmunoScintography and Radioguided Surgery and the former President of the International Association of Radiopharmacology. He has published six books and more than 180 articles in peer-reviewed journals covering virtually all aspects of diagnostic and therapeutic Nuclear Medicine, both clinical and experimental, with a major focus on molecular targeting with radioactive tracers.
H. William Strauss, M.D.
Dr. Strauss is the Clinical Director, Nuclear Medicine Service at Memorial Sloan-Kettering Cancer Center. Formerly Dr. Strauss was Professor of Radiology and Chief of Nuclear Medicine at Stanford University School of Medicine and Vice President of Bristol-Myers-Squibb from 1992 to 1994. Prior to that, Dr. Strauss was Professor at the Harvard Medical School and Massachusetts General Hospital for almost two decades. The recipient of numerous awards, his recent honors include the Distinguished Service Award of the Society of Nuclear Medicine and distinguished Johns Hopkins Nuclear Medicine Alumni Award. He has served on many national and international committees and boards such as Advisory Committee of Federal Drug Administration (1979-1987) and Medical Expert Advisory Committee on Disciplinary Matters, Board of Registration in Medicine (1988-1992). He serves on the editorial boards of the American Journal of Cardiology and Journal of Nuclear Medicine. He is the author of over 450 papers and articles and editors of several major books.
Posted 10/08/2018 - Molecular Targeting Technologies, Inc. Wins Exclusive License for Novel Neuroendocrine Neoplasm Drug from NIH.read more
Posted 9/29/2017 - Molecular Targeting Technologies, Inc. Wins Award from “RESI Boston 2017” Innovation Challengeread more
Posted 6/27/2017 - TumorVue Image Wins the 2017 MILabs Image of the Year Awardread more
Posted 12/05/2016 - MTTI announces that response of colorectal cancer to treatment can be detected as early as one day after treatmentread more
Posted 08/18/2016 - New milestone: 癌症治療新曙光 國衛院與泰緯生技攜手抗癌read more
Posted 01/08/2016 - MTTI Receives Multimodality DPA Technology Patentread more
Posted 05/15/2015 - MTTI receives expanded patent approval for 99mTc-Duramycin technology to target programmed cell deathread more
Posted 05/08/2015 - World news on Novel Cancer Therapeutic
Posted 05/06/2015 - MTTI announces the capability of PSVue 794 to non-invasively image arthritisread more
Posted 04/22/2015 - MTTI Smith Molecular Probe on WSBT View Video
Posted 04/22/2015 - Dr. Bradley Smith speaks about the potential clinical applications of Cell-Death Imaging Agent View Video
Posted 04/18/2015 - 國家衛生研究院暨美國Molecular Targeting Technologies公司於2015美國癌症研究協會(AACR)共同發表新穎癌症治療法合作案之研發成果read more
Posted 04/17/2015 - MTTI and National Health Research Institutes Present a Novel Cancer Therapeutic at 2015 AACRread more
Posted 10/24/2014 - MTTI receives patent approval for technology to identify dead and dying cells in patientsread more
Posted 08/04/2014 - MTTI and National Health Research Institutes Have Joined Forces in Developing Novel Cancer Therapeuticsread more
Posted 08/04/2014 - 國 家衛生研究院暨美國 家衛生研究院暨美國 家衛生研究院暨美國 家衛生研究院暨美Molecular Targeting Molecular Targeting Molecular Targeting 公司 合作進行新穎癌症治療法之研發 合作進行新穎癌症治療法之研發 合作進行新穎癌症治療法之研發 合作進行新穎癌症治療法之研發 合read more
Posted 06/13/2014 - Chris Pak received 2014 Lifetime Achievement Award from CASNMMIread more
Posted 02/26/14 - Philadelphia Business Journal Recognizes MTTI for 2013 Innovation Awardread more
Posted 06/21/13 - Real time assessment of tumor response presentation wins the Innovation Competitionread more
Posted 11/28/12 - Notre Dame and MTTI Awarded Patent for Fluorescent Dye Technologyread more
Posted 8/2/12 - MTTI licenses Novel Targeting Agent from Medical College of Wisconsinread more
Posted 5/10/11 - MTTI licenses robust NIR dye technology from Massachusetts General Hospitalread more
Posted 10/12/10 - Jefferson Awarded Multi-Million Dollar NIH Grantread more
Posted 9/22/10- Zn_DPA Cardiac Imaging Study Wins Competitionread more
Posted 3/19/10 - University of Notre Dame and MTTI in Dealread more
Posted 3/1/10 - Molecular Targeting Technologies, Inc. Licenses Cell Targeting Technology from the University of Notre Dameread more
Posted 3/2/09 - LI-COR Sciences and MTTI Introduce CellVue® Dye Kits for Fluorescent Labeling of Cell Membranesread more
Posted 8/23/08 - MTTI has B-Bridge Inc. as a distributor for Japan.read more
Posted 8/22/08 - MTTI has engaged Dundee Cell Products as a distributor for Europe.read more
Posted 4/22/08 - MTTI will collaborate with Bexion to develop a novel nanovesicle for molecular imaging of tumors.read more
Posted 1/8/08 - MTTI and GENSEEN Partner to Develop Breast Cancer Gene Imaging Agentread more